abstract |
The present invention relates to the use of substituted dihydroimidazolones, particularly [1-(4-Chlorophenyl)-4(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one] (AWD 131-138) or a physiologically acceptable salt thereof for the treatment of epilepsy in dogs. |